{"drug_name": "Lepirudin", "question": "What is Lepirudin?", "answer": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}}
{"drug_name": "Lepirudin", "question": "What is the mechanism of action of Lepirudin?", "answer": "Lepirudin is a direct thrombin inhibitor that binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex, which blocks thrombin's protease activity and inhibits the coagulation process.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}}
{"drug_name": "Lepirudin", "question": "What are the primary indications for Lepirudin?", "answer": "Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) and for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}}
{"drug_name": "Lepirudin", "question": "What is the primary target of Lepirudin?", "answer": "The primary target of Lepirudin is thrombin.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}}
{"drug_name": "Lepirudin", "question": "With what other drug is Lepirudin intended for use in patients with acute coronary syndromes?", "answer": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes.", "ground_truth_context": {"Name": "Lepirudin", "Description": "Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor. It is produced in yeast cells and is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease. It is also indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation.", "MoA": "Lepirudin is a direct thrombin inhibitor. It binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex. This blocks the protease activity of thrombin and inhibits the coagulation process. It can inhibit thrombin in both its clot-bound or free states.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "Lepirudin is intended for use with aspirin in patients with acute coronary syndromes (ACS).", "Formula": "N/A"}}
{"drug_name": "Cetuximab", "question": "What is Cetuximab?", "answer": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}}
{"drug_name": "Cetuximab", "question": "What is the mechanism of action of Cetuximab?", "answer": "Cetuximab binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands, thereby inhibiting EGFR activation and downstream signaling pathways.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}}
{"drug_name": "Cetuximab", "question": "What is the primary target of Cetuximab?", "answer": "The primary target of Cetuximab is the epidermal growth factor receptor (EGFR).", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}}
{"drug_name": "Cetuximab", "question": "For which conditions is Cetuximab approved?", "answer": "Cetuximab is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}}
{"drug_name": "Cetuximab", "question": "With which other therapies can Cetuximab be combined?", "answer": "Cetuximab can be combined with platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "ground_truth_context": {"Name": "Cetuximab", "Description": "Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). It is approved for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.", "MoA": "Cetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands. Upon binding to domain III of EGFR, cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat). This inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion. Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production, and results in internalization of the antibody-receptor complex leading to an overall downregulation of EGFR expression.", "Targets": "Epidermal growth factor receptor (EGFR)", "Physical_State": "N/A", "Interactions": "Cetuximab is administered as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, leucovorin, fluorouracil, irinotecan, and encorafenib.", "Formula": "N/A"}}
{"drug_name": "Dornase alfa", "question": "What is Dornase alfa?", "answer": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Dornase alfa", "question": "How is Dornase alfa produced?", "answer": "Dornase alfa is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Dornase alfa", "question": "What is the mechanism of action of Dornase alfa?", "answer": "Dornase alfa endonucleolytically cleaves extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Dornase alfa", "question": "What does Dornase alfa target?", "answer": "Dornase alfa targets extracellular DNA.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Dornase alfa", "question": "What improves the viscosity and viscoelasticity of purulent sputum in individuals with CF?", "answer": "The breakdown of extracellular DNA by Dornase alfa improves the viscosity and viscoelasticity of purulent sputum in individuals with CF.", "ground_truth_context": {"Name": "Dornase alfa", "Description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. It cleaves extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, enzymatic breakdown of extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "MoA": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Its breakdown of extracellular DNA appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.", "Targets": "Extracellular DNA", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Denileukin diftitox", "question": "What is Denileukin diftitox?", "answer": "Denileukin diftitox is a recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133).", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Denileukin diftitox", "question": "How is Denileukin diftitox produced?", "answer": "It is produced in an E. coli expression system.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Denileukin diftitox", "question": "What is the mechanism of action of Denileukin diftitox?", "answer": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Denileukin diftitox", "question": "What does Denileukin diftitox bind to?", "answer": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Denileukin diftitox", "question": "Which cells does the diphtheria toxin associated with Ontak selectively kill?", "answer": "The diphtheria toxin associated with Ontak selectively kills the IL-2 bearing cells.", "ground_truth_context": {"Name": "Denileukin diftitox", "Description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "MoA": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "Targets": "High-affinity IL-2 receptor complex; IL-2 receptor (Tac) subunit", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Etanercept", "question": "What is Etanercept?", "answer": "Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Etanercept", "question": "How is Etanercept produced?", "answer": "Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Etanercept", "question": "What is the mechanism of action of Etanercept?", "answer": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Etanercept", "question": "What specific target does Etanercept bind to?", "answer": "Etanercept binds to the active trimeric form of tumor necrosis factor (TNF) molecules.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Etanercept", "question": "What are some inflammatory conditions Etanercept is used to treat?", "answer": "Etanercept is used to treat or manage rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA), chronic moderate to severe plaque psoriasis, and psoriatic arthritis.", "ground_truth_context": {"Name": "Etanercept", "Description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. It is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system and consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).", "MoA": "Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. It is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.", "Targets": "Tumor necrosis factor (TNF) molecules (specifically the active trimeric form).", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Bivalirudin", "question": "What type of compound is Bivalirudin?", "answer": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor).", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Bivalirudin", "question": "How is Bivalirudin administered?", "answer": "Bivalirudin is administered intravenously.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Bivalirudin", "question": "What is the mechanism of action of Bivalirudin?", "answer": "Bivalirudin inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Bivalirudin", "question": "What is the primary target of Bivalirudin?", "answer": "The primary target of Bivalirudin is thrombin.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Bivalirudin", "question": "What crucial step in thrombus formation does thrombin facilitate?", "answer": "Thrombin activates fibrinogen into fibrin, which is the crucial step in the formation of thrombus.", "ground_truth_context": {"Name": "Bivalirudin", "Description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously.", "MoA": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "Targets": "Thrombin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Leuprolide", "question": "What type of compound is Leuprolide?", "answer": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH).", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron\u2122.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}}
{"drug_name": "Leuprolide", "question": "What is the primary target of Leuprolide?", "answer": "Leuprolide primarily targets the Gonadotropin-releasing hormone receptor (GnRHR).", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron\u2122.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}}
{"drug_name": "Leuprolide", "question": "When was Leuprolide first approved and what was its original tradename?", "answer": "Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron\u2122.", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron\u2122.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}}
{"drug_name": "Leuprolide", "question": "How does Leuprolide achieve its therapeutic benefit?", "answer": "After 2-4 weeks of continuous GnRHR stimulation, leuprolide causes feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit.", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron\u2122.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}}
{"drug_name": "Leuprolide", "question": "For which conditions is Leuprolide indicated?", "answer": "Leuprolide is indicated for the treatment of advanced prostate cancer, central precocious puberty, initial treatment of endometriosis symptoms (in combination with oral norethisterone), and preoperative hematological improvement of anemic patients with uterine leiomyomata (in combination with iron supplementation).", "ground_truth_context": {"Name": "Leuprolide", "Description": "Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH) that contains a single D-amino acid (D-leucyl) residue, which increases its circulating half-life to approximately three hours. It binds to the GnRH receptor (GnRHR) and induces downstream modulation of gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, providing clinical efficacy in conditions like advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron\u2122.", "MoA": "As a GnRHR agonist, leuprolide initially activates downstream LH and FSH release. After 2-4 weeks of continuous GnRHR stimulation, it results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.", "Targets": "Gonadotropin-releasing hormone receptor (GnRHR)", "Physical_State": "Injectable solution for subcutaneous and intramuscular administration", "Interactions": "Can be used in combination with oral norethisterone for the initial treatment of endometriosis symptoms. It can also be combined with iron supplementation for the preoperative hematological improvement of anemic patients with uterine leiomyomata.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2a", "question": "What is Peginterferon alfa-2a?", "answer": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2a", "question": "What is the mechanism of action of Peginterferon alfa-2a?", "answer": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize, which activates the JAK/STAT pathway to increase expression of genes involved in the innate antiviral response.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2a", "question": "What are the primary targets of Peginterferon alfa-2a?", "answer": "The primary targets of Peginterferon alfa-2a are human type 1 interferon receptors.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2a", "question": "For which conditions is Peginterferon alfa-2a indicated?", "answer": "Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs and as a monotherapy for adult patients with chronic hepatitis B infection.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2a", "question": "What is the tradename under which Peginterferon alfa-2a is available as a fixed dose injector?", "answer": "Peginterferon alfa-2a is available as a fixed dose injector under the tradename Pegasys.", "ground_truth_context": {"Name": "Peginterferon alfa-2a", "Description": "Peginterferon alfa-2a is a form of recombinant interferon derived from the alfa-2a moiety of recombinant human interferon, historically used as part of combination therapy to treat chronic Hepatitis C and also indicated as a monotherapy for adult patients with chronic hepatitis B infection.", "MoA": "Peginterferon alfa-2a binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response.", "Targets": "Human type 1 interferon receptors", "Physical_State": "Available as a fixed dose injector (tradename Pegasys)", "Interactions": "Used alongside [DB00811] (e.g., ribavirin) or other antiviral drugs for Hepatitis C.", "Formula": "N/A"}}
{"drug_name": "Alteplase", "question": "What type of drug is Alteplase?", "answer": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Alteplase", "question": "How does Alteplase convert plasminogen to plasmin?", "answer": "In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Alteplase", "question": "What are the molecular targets of Alteplase?", "answer": "Alteplase targets plasminogen and fibrin.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Alteplase", "question": "When was Alteplase first approved by the FDA and for what initial purpose?", "answer": "Alteplase was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Alteplase", "question": "What is the role of plasmin after it is formed by Alteplase?", "answer": "Plasmin degrades the fibrin matrix of the thrombus and promotes clot dissolution.", "ground_truth_context": {"Name": "Alteplase", "Description": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells. It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).", "MoA": "Alteplase is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin in a fibrin-dependent process. In the presence of fibrin clots, alteplase binds to fibrin and cleaves the arginine-valine bond at positions 560 and 561 of plasminogen, converting it into its active form, plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus and promotes clot dissolution. Alteplase initiates local fibrinolysis with limited systemic proteolysis.", "Targets": "Plasminogen, Fibrin", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sermorelin", "question": "What is Sermorelin acetate?", "answer": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sermorelin", "question": "What is the mechanism of action of Sermorelin?", "answer": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sermorelin", "question": "What receptor does Sermorelin bind to?", "answer": "Sermorelin binds to the growth hormone releasing hormone receptor.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sermorelin", "question": "How does Sermorelin affect growth hormone secretion?", "answer": "Sermorelin mimics native GRF in its ability to stimulate growth hormone secretion.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sermorelin", "question": "What type of molecule is Sermorelin acetate?", "answer": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide.", "ground_truth_context": {"Name": "Sermorelin", "Description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.", "MoA": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "Targets": "Growth hormone releasing hormone receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n1", "question": "What is Interferon alfa-n1?", "answer": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n1", "question": "How does Interferon alfa-n1 differ from recombinant alpha interferons?", "answer": "Interferon alfa-n1 differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n1", "question": "What is the mechanism of action of Interferon alfa-n1?", "answer": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n1", "question": "What are the primary targets of Interferon alfa-n1's binding action?", "answer": "Interferon alfa-n1 primarily targets type I interferon receptors (IFNAR1 and IFNAR2c).", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n1", "question": "Which kinases are activated when type I interferon receptors dimerize after binding with Interferon alfa-n1?", "answer": "Two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2) are activated.", "ground_truth_context": {"Name": "Interferon alfa-n1", "Description": "Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, Stat2", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Darbepoetin alfa", "question": "What is Darbepoetin alfa?", "answer": "Darbepoetin alfa is human erythropoietin with 2 amino acid substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD), produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Darbepoetin alfa", "question": "How does Darbepoetin alfa stimulate erythropoiesis?", "answer": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin, interacting with progenitor stem cells to increase red cell production.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Darbepoetin alfa", "question": "What occurs when erythropoietin binds to its receptor?", "answer": "Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Darbepoetin alfa", "question": "What is the function of activated STAT proteins in the mechanism of action?", "answer": "Activated STAT proteins are translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Darbepoetin alfa", "question": "What is the molecular weight of Darbepoetin alfa?", "answer": "The molecular weight of Darbepoetin alfa is 37 kD.", "ground_truth_context": {"Name": "Darbepoetin alfa", "Description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "MoA": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "Targets": "Erythropoietin receptor, progenitor stem cells", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Urokinase", "question": "What is the mechanism of action of Urokinase?", "answer": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Urokinase", "question": "When was Urokinase granted FDA approval?", "answer": "Urokinase was granted FDA approval on 16 January 1978.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Urokinase", "question": "What kind of peptide is Urokinase?", "answer": "Urokinase is an endogenous peptide.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Urokinase", "question": "How are the two chains of Urokinase connected after cleavage?", "answer": "Urokinase remains connected between these 2 chains by a sulfhydryl bond.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Urokinase", "question": "What is the target of Urokinase?", "answer": "Urokinase targets plasminogen.", "ground_truth_context": {"Name": "Urokinase", "Description": "Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.", "MoA": "Urokinase is a serine protease. It cleaves plasminogen to form the active fibrinolytic protease, plasmin.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Goserelin", "question": "What is Goserelin?", "answer": "Goserelin is a synthetic hormone.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Goserelin", "question": "How does Goserelin work in men?", "answer": "In men, Goserelin stops the production of the hormone testosterone, which may stimulate the growth of cancer cells.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Goserelin", "question": "What is the mechanism of action of Goserelin?", "answer": "Goserelin is a synthetic decapeptide analogue of LHRH that acts as a potent inhibitor of pituitary gonadotropin secretion, resulting in sustained suppression of LH and serum testosterone levels.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Goserelin", "question": "What happens to hormone levels when Goserelin medication is stopped?", "answer": "When the medication is stopped, hormone levels return to normal.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Goserelin", "question": "How does Goserelin affect hormone levels in women?", "answer": "In women, goserelin decreases the production of the hormone estradiol to levels similar to a postmenopausal state.", "ground_truth_context": {"Name": "Goserelin", "Description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "MoA": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "Targets": "Pituitary gonadotropin secretion, LHRH, LH, testosterone, estradiol", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Reteplase", "question": "What is Reteplase?", "answer": "Reteplase is a human tissue plasminogen activator, purified, glycosylated, with 355 residues purified from CHO cells, considered a \"third-generation\" thrombolytic agent.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Reteplase", "question": "What is the mechanism of action of Reteplase?", "answer": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain, then its protease domain cleaves the Arg/Val bond in plasminogen to form plasmin, which degrades the fibrin matrix of the thrombus.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Reteplase", "question": "Which specific domains of human tPA are retained in Reteplase?", "answer": "Reteplase retains the activity-related kringle-2 and serine protease domains of human tPA.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Reteplase", "question": "What domains are deleted from Reteplase compared to native human tPA?", "answer": "Three domains are deleted from retavase: kringle-1, finger, and epidermal growth factor (EGF).", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Reteplase", "question": "What molecule does Reteplase cleave to initiate its thrombolytic action?", "answer": "Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin.", "ground_truth_context": {"Name": "Reteplase", "Description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "MoA": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "Targets": "Plasminogen", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Erythropoietin", "question": "What is Erythropoietin (EPO)?", "answer": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-\u03b31 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-\u03b31", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Erythropoietin", "question": "What is the primary mechanism of action of Erythropoietin or epoetin alfa?", "answer": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways, primarily involving JAK2 and STAT5.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-\u03b31 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-\u03b31", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Erythropoietin", "question": "What is the molecular weight of Epoetin alfa?", "answer": "Epoetin alfa has a molecular weight of approximately 30,400 daltons.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-\u03b31 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-\u03b31", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Erythropoietin", "question": "What are the specific clinical conditions for which epoetin alfa is indicated?", "answer": "Epoetin alfa is indicated for the treatment of anemia due to Chronic Kidney Disease, anemia due to zidovudine in patients with HIV-infection, anemia due to the effects of concomitant myelosuppressive chemotherapy, and for the reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-\u03b31 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-\u03b31", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Erythropoietin", "question": "Which intracellular signaling proteins are activated by erythropoietin and epoetin alfa through JAK2-mediated tyrosine phosphorylation?", "answer": "Erythropoietin and epoetin alfa activate Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-\u03b31, and STAT5 via JAK2-mediated tyrosine phosphorylation.", "ground_truth_context": {"Name": "Erythropoietin (EPO)", "Description": "Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures. It has a molecular weight of approximately 30,400 daltons. Epoetin alfa biosimilars, such as Retacrit (epoetin alfa-epbx or epoetin zeta), also exist.", "MoA": "Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. Upon binding to EPO-R, a conformational change brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity, leading to their phosphorylation. JAK2 then phosphorylates tyrosine residues in the cytoplasmic domain of the EPO-R, which serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins, including STAT5. Phosphorylated STAT5 dissociates from the EPO-R, dimerizes, and translocates to the nucleus to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. Erythropoietin and epoetin alfa also activate Shc, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-\u03b31 via JAK2-mediated tyrosine phosphorylation.", "Targets": "Erythropoietin receptor (EPO-R), Janus family tyrosine protein kinase 2 (JAK2), STAT5, Bcl-x, Shc, phosphatidylinositol 3-kinase (PI3K), phospholipase C-\u03b31", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Salmon calcitonin", "question": "What is Salmon calcitonin?", "answer": "Salmon calcitonin is a synthetic peptide, 32 residues long, formulated as a nasal spray.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Salmon calcitonin", "question": "What is the mechanism of action of Salmon calcitonin?", "answer": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Salmon calcitonin", "question": "What are the primary targets of Salmon calcitonin?", "answer": "The primary target of Salmon calcitonin is the calcitonin receptor, found primarily in osteoclasts.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Salmon calcitonin", "question": "How many residues long is the Salmon calcitonin peptide?", "answer": "Salmon calcitonin is a synthetic peptide 32 residues long.", "ground_truth_context": {"Name": "Salmon calcitonin", "Description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "MoA": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "Targets": "calcitonin receptor (found primarily in osteoclasts)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n3", "question": "What is Interferon alfa-n3?", "answer": "Interferon alfa-n3 is purified, natural human interferon alpha proteins consisting of 3 forms or polymorphisms (2a, 2b, and 2c), with 166 residues, some of which are glycosylated, and a molecular weight ranging from 16 kD to 27 kD.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n3", "question": "Which receptors does Interferon alpha bind to?", "answer": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c).", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n3", "question": "What happens after type I interferon receptors are activated by Interferon alpha binding?", "answer": "Upon dimerization, the receptors activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2), which then transphosphorylate themselves and phosphorylate the receptors.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n3", "question": "What are the specific targets of Interferon alfa-n3 in its mechanism of action?", "answer": "The specific targets are Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Interferon alfa-n3", "question": "How many forms or polymorphisms does Interferon alfa-n3 consist of?", "answer": "Interferon alfa-n3 consists of 3 forms or polymorphisms including 2a, 2b and 2c.", "ground_truth_context": {"Name": "Interferon alfa-n3", "Description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "MoA": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "Targets": "Type I interferon receptors (IFNAR1 and IFNAR2c), Jak1, Tyk2, Stat1, and Stat2.", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Pegfilgrastim", "question": "What is Pegfilgrastim?", "answer": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Pegfilgrastim", "question": "What is Pegfilgrastim approved for?", "answer": "Pegfilgrastim is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Pegfilgrastim", "question": "What is the mechanism of action of Pegfilgrastim?", "answer": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage to stimulate the proliferation, differentiation, and activation of neutrophils.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Pegfilgrastim", "question": "What is the primary target of Pegfilgrastim?", "answer": "The primary target of Pegfilgrastim is the G-CSF receptor.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Pegfilgrastim", "question": "How is Pegfilgrastim typically administered?", "answer": "Pegfilgrastim is typically administered via a subcutaneous injection.", "ground_truth_context": {"Name": "Pegfilgrastim", "Description": "Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Due to a longer half-life and slower elimination rate than filgrastim, pegfilgrastim requires less frequent dosing than filgrastim; however, pegfilgrastim has a comparable pharmacological activity to filgrastim and binds to the G-CSF receptor to stimulate the proliferation, differentiation, and activation of neutrophils. First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.", "MoA": "Pegfilgrastim mimics the biological actions of G-CSF and binds to the G-CSF receptor expressed on cells of myeloid lineage, such as granulocytic precursors and mature neutrophils. Upon binding of the ligand, G-CSF receptor undergoes a conformational change and activates several downstream signalling pathways including JAK/STAT, PI3K/AKT and MAPK/ERK. These pathways work to increase proliferation and differentiation of granulocyte progenitor cells, induce maturation of the progenitor cells, and enhance survival and function of mature neutrophils.", "Targets": "G-CSF receptor", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sargramostim", "question": "What is Sargramostim?", "answer": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast, which is a glycoprotein of 127 residues.", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sargramostim", "question": "What is the mechanism of action of Sargramostim?", "answer": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway.", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sargramostim", "question": "What receptor does Sargramostim target?", "answer": "Sargramostim targets the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R).", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Sargramostim", "question": "What is the result of the signal transduction pathway stimulated by Sargramostim?", "answer": "This leads to the production of hemopoietic cells and neutrophils.", "ground_truth_context": {"Name": "Sargramostim", "Description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "MoA": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "Targets": "Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R)", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2b", "question": "What is Peginterferon alfa-2b?", "answer": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2b", "question": "What is the mechanism of action of Peginterferon alfa-2b?", "answer": "Peginterferon alfa-2b binds to and activates human type 1 interferon receptors causing them to dimerize, which activates the JAK/STAT pathway and may also activate the nuclear factor \nR\nB pathway.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2b", "question": "What are the targets of Peginterferon alfa-2b?", "answer": "The targets of Peginterferon alfa-2b are human type 1 interferon receptors.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2b", "question": "What is the physical state and tradename of Peginterferon alfa-2b?", "answer": "Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron).", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}}
{"drug_name": "Peginterferon alfa-2b", "question": "With which drugs is Peginterferon alfa-2b indicated for combination therapy?", "answer": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "ground_truth_context": {"Name": "Peginterferon alfa-2b", "Description": "Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Its use has largely declined since newer interferon-free antiviral therapies have been developed, and it is no longer recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) for the treatment of Hepatitis C. It is available as a variable dose injectable product (tradename Pegintron) and was approved in 2001 by the FDA.", "MoA": "Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway, which increases expression of multiple genes involved in the innate antiviral response. Peginterferon alfa-2b may also activate the nuclear factor \nR\nB pathway.", "Targets": "human type 1 interferon receptors", "Physical_State": "variable dose injectable product", "Interactions": "Peginterferon alfa-2b is indicated for combination with Ribavirin (DB00811) and a NS3/4A protease inhibitor for genotype 1, or without a NS3/4A protease inhibitor for genotypes 2-6.", "Formula": "N/A"}}
{"drug_name": "Asparaginase Escherichia coli", "question": "What is Asparaginase Escherichia coli?", "answer": "Asparaginase derived from _Escherichia coli_ is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Asparaginase Escherichia coli", "question": "For what condition is L-asparaginase of _E. coli_ primarily used?", "answer": "L-asparaginase of _E. coli_ is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Asparaginase Escherichia coli", "question": "How does Asparaginase Escherichia coli lead to apoptotic cell death in leukemic cells?", "answer": "Therapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Asparaginase Escherichia coli", "question": "Why are lymphoblastic leukemic cells particularly susceptible to asparagine depletion?", "answer": "Lymphoblastic leukemic cells lack the asparagine synthetase enzyme and cannot produce asparagine _de novo_, relying on exogenous asparagine for protein synthesis and cell survival.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Asparaginase Escherichia coli", "question": "What are the available administration routes for L-asparaginase from _E. coli_?", "answer": "It is available as intramuscular or intravenous injections.", "ground_truth_context": {"Name": "Asparaginase Escherichia coli", "Description": "Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It has clinically shown to exhibit antitumor actions in models of leukaemias and is marketed for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It works by depleting levels of asparagine in lymphoblastic leukemic cells, promoting apoptotic cell death.", "MoA": "Asparaginase from _E. coli_ depletes plasma levels of asparagine in leukemic cells by converting L-asparagine to L-aspartic acid and ammonia. This leads to reduced DNA, RNA and protein synthesis, inhibition of cell growth, and activation of apoptotic cell-death mechanisms. Leukemic cells are affected as they lack asparagine synthetase and rely on exogenous asparagine, while normal cells can synthesize it.", "Targets": "L-asparagine", "Physical_State": "Available as intramuscular or intravenous injections", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Thyrotropin alfa", "question": "What is Thyrotropin alfa used for?", "answer": "Thyrotropin alfa is used in performing certain tests in patients who have or have had thyroid cancer and also along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Thyrotropin alfa", "question": "What is the mechanism of action of Thyrotropin alfa?", "answer": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues, stimulating radioactive iodine uptake for better radiodiagnostic imaging.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Thyrotropin alfa", "question": "What are the subunits that comprise Thyrotropin alfa?", "answer": "Thyrotropin alfa is comprised of an alpha subunit of 92 amino acid residues and a beta subunit of 112 residues.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Thyrotropin alfa", "question": "What is the amino acid sequence of thyrotropin alfa identical to?", "answer": "The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
{"drug_name": "Thyrotropin alfa", "question": "What are the targets of Thyrotropin alfa?", "answer": "Thyrotropin alfa targets thyrotropin receptors.", "ground_truth_context": {"Name": "Thyrotropin alfa", "Description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "MoA": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "Targets": "Thyrotropin receptors", "Physical_State": "N/A", "Interactions": "N/A", "Formula": "N/A"}}
